MedTrace Logo

Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease

NCT03471169 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3500

Last updated 2018-03-20

No results posted yet for this study

Summary

To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.

Conditions

  • Cerebrovascular Disease

Interventions

DRUG

Desirable TEG

Change the type and dose of antithrombotic therapy and obtain desirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.

DRUG

Undesirable TEG

Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Qian Zhang, 1 · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-12-01
Completion
2018-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03471169 on ClinicalTrials.gov